Teladoc Health, Inc. insider trading
Every open-market purchase and sale by Teladoc Health, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Teladoc Health, Inc.’s insiders pay?
From September 14, 2015 to September 14, 2026, 36 insiders reported 9 open-market purchases and 190 sales not made under a pre-set plan in Teladoc Health, Inc. Twelve months after each purchase was reported, the shares were +27.0% against the S&P 500 on average (median −4.0%), over 8 purchases with a full year of prices; 50% beat the index. After sales, the shares moved −46.5% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on September 15, 2015 into $16,687 by November 2, 2026, +4.7% a year. It held shares 32% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $20,957 (+6.9% a year), and held throughout $45,833 (+14.7%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Vandervoort Adam C | CHIEF LEGAL OFFICER, SECRETARY | 0 | — | — | 25 | −40.9% (21) | September 3, 2026 |
| Murthy Mala | CHIEF FINANCIAL OFFICER | 0 | — | — | 19 | −57.3% (19) | September 3, 2025 |
| Geshuri Arnnon | CHIEF PEOPLE OFFICER | 0 | — | — | 17 | −58.8% (17) | September 4, 2024 |
| Gorevic Jason N | CHIEF EXECUTIVE OFFICER | 0 | — | — | 12 | −32.7% (12) | March 5, 2024 |
| Trencher Daniel | CHIEF STRATEGY OFFICER | 0 | — | — | 11 | −62.1% (11) | September 4, 2024 |
| Verstraete Stephany | CHIEF MARKETING OFFICER | 0 | — | — | 11 | −63.1% (11) | September 4, 2024 |
| Bliss Kelly | President, U.S. Group Health | 0 | — | — | 9 | −44.4% (5) | September 3, 2026 |
| Turitz Andrew | EVP, CORPORATE DEVELOPMENT | 0 | — | — | 9 | −37.3% (9) | September 4, 2024 |
| Divita Charles III | CHIEF EXECUTIVE OFFICER | 0 | — | — | 8 | −30.8% (1) | September 14, 2026 |
| Napolitano Richard J | CHIEF ACCOUNTING OFFICER | 0 | — | — | 8 | −68.1% (8) | March 5, 2024 |
| Nueno Carlos | President, International | 0 | — | — | 8 | −44.2% (4) | September 3, 2026 |
| Waters Michael Willem | CHIEF OPERATING OFFICER | 0 | — | — | 8 | −54.4% (8) | September 4, 2024 |
| Raman-Tangella Vidya | CHIEF MEDICAL OFFICER | 0 | — | — | 7 | −64.3% (7) | August 5, 2024 |
| Jensen Claus Torp | CHIEF INNOVATION OFFICER | 0 | — | — | 6 | −72.3% (6) | September 6, 2023 |
| Kornwasser Laizer | Advisor to the CEO | 0 | — | — | 6 | −54.6% (6) | August 5, 2024 |
| Hirschhorn Mark | Executive VP, COO & CFO | 0 | — | — | 3 | +54.0% (3) | December 4, 2017 |
| King Michael H. | Chief Sales Officer | 1 | +2.3% (1) | 100% | 2 | +55.9% (2) | September 2, 2016 |
| Nanis Nikolaos P. | Chief Technology Officer | 0 | — | — | 3 | −59.0% (3) | June 4, 2024 |
| Rodrigues Fernando M. | President of BetterHelp | 0 | — | — | 3 | −52.8% (2) | June 3, 2026 |
| Sides David William | Chief Operating Officer | 0 | — | — | 3 | −72.5% (3) | August 2, 2021 |
| Goldstein Michael | Director | 0 | — | — | 2 | +78.0% (2) | March 7, 2019 |
| Mckinley Thomas | Director | 2 | −18.2% (2) | 0% | 0 | — | September 13, 2024 |
| Taneja Hemant | Director | 0 | — | — | 2 | −82.2% (2) | March 15, 2021 |
| Wang Yulun | Head of Research & Development | 0 | — | — | 2 | −76.6% (2) | December 16, 2020 |
| Bucaria Michelle | Chief Human Resources Officer | 0 | — | — | 1 | +96.5% (1) | March 15, 2019 |
| Catapano Joseph Ronald | Chief Accounting Officer | 0 | — | — | 1 | −52.1% (1) | October 3, 2025 |
| Chp III Management, L.L.C. | 10% owner | 0 | — | — | 1 | +94.2% (1) | December 15, 2016 |
| Felsenthal Martin R | Director | 1 | +96.7% (1) | 100% | 0 | — | March 18, 2016 |
| Frist William H. | Director | 1 | −29.9% (1) | 0% | 0 | — | September 14, 2015 |
| Levy Lewis | Chief Medical Officer | 0 | — | — | 1 | −64.5% (1) | July 16, 2020 |
| Mcclennen Peter A | President | 0 | — | — | 1 | +36.1% (1) | March 9, 2018 |
| Mead Dana G JR. | Director | 1 | +96.7% (1) | 100% | 0 | — | March 18, 2016 |
| Outland James K | Director | 1 | +96.7% (1) | 100% | 0 | — | March 18, 2016 |
| Paulus Kenneth H | Director | 1 | — | — | 0 | — | November 17, 2025 |
| Smith Mark Douglas | Director | 1 | −10.3% (1) | 0% | 0 | — | August 19, 2024 |
| Trident Capital Fund VI LP | 10% owner | 0 | — | — | 1 | +48.9% (1) | January 26, 2017 |
When several insiders traded Teladoc Health, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Teladoc Health, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 2 buying crowds with six months of prices, it averaged +17.5% against the index. After 7 selling crowds, +4.5%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| March 31, 2023 | 9 selling | −9.9% | −34.0% | −73.1% |
| March 31, 2022 | 7 selling | −36.5% | −44.6% | −57.0% |
| December 31, 2020 | 3 selling | −18.4% | −34.6% | −82.8% |
| August 31, 2020 | 3 selling | −11.9% | −15.9% | −64.2% |
| March 29, 2018 | 5 selling | +39.8% | +93.3% | +22.4% |
| January 31, 2017 | 4 selling | +19.6% | +53.0% | +60.7% |
| August 31, 2016 | 4 selling | +1.0% | +14.2% | +72.0% |
| March 31, 2016 | 3 buying | +64.9% | +82.2% | +145.2% |
| November 30, 2015 | 2 buying | −32.5% | −47.2% | −23.0% |